PHARNEXT SA (ALPHA.PA)

Company Profile

Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.

Company Info

PHARNEXT SA

14 rue de la Republique

Suresnes ILE-DE-FRANCE

P: 33141092230

Employees: 0

Website: https://www.pharnext.com/fr/